Biogen, Bio-Thera present positive phase 3 data for their Actemra biosimilar candidate
seekingalpha.com
finance
2022-06-03 13:11:32

Jun. 03, 2022 9:11 AM ETBiogen Inc. (BIIB)By: Anuron Mitra, SA News Editor peterschreiber.media/iStock via Getty Images Biogen (NASDAQ:BIIB) and commercialization partner Bio-Thera Solutions on Friday presented what they deemed to be positive phase 3 data for BIIB800, their biosimilar candidate to Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) arthritis drug Actemra. The data was presented at the Annual European Congress of Rheumatology. Data from the late-stage comparative trial showed that the biosimilar candidate had equivalent efficacy and a comparable safety and immunogenicity profile to Actemra.
